NIH R01 · 2025
PROJECT SUMMARY Over 250,000 kidney transplant (KT) recipients depend on lifelong immunosuppressive therapy to prevent rejection and graft failure. However, immunosuppression increases the risk of complications such as infections, cancer, and cardiovascular disease (CVD), which together account for >70% of deaths in KT patients. To optimize transplant outcomes while minimizing immunosuppression-associated adverse drug events (ADEs), clinicians aim to choose the most appropriate immunosuppression regimen for the individual recipient's risk profile. Nonetheless, this practice is often empirical and rudimentary because little clinical evidence guides it. Our previous study found substantial…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.